Emerging therapeutic targets in diabetic vascular disease

Ann Marie Schmidt, David Stern

Research output: Contribution to journalReview article

Abstract

Diabetes affects nearly 14 m persons in the United States alone; worldwide, the incidence of diabetes is on the rise. It is a heterogeneous disorder of impaired insulin production/sensitivity and is associated with enhanced development of accelerated micro- and macrovasculature disease. Multiple epidemiologic studies have demonstrated that even after correction of typical risk factors, such as obesity, hyperlipidaemia, hypertension and cigarette smoking, patients with diabetes continue to experience enhanced risk of cardiovascular complications [1-2]. Thus, delineation of the factors specific and unique to diabetes that impart increased risk for the development of aggressive heart attacks and strokes is critical for the development of targeted therapy to prevent/delay accelerated macrovascular disease in diabetic patients.

Original languageEnglish (US)
Pages (from-to)483-493
Number of pages11
JournalExpert Opinion on Therapeutic Targets
Volume3
Issue number3
DOIs
StatePublished - Sep 1 1999
Externally publishedYes

Fingerprint

Diabetic Angiopathies
Medical problems
Microvessels
Hyperlipidemias
Insulin Resistance
Epidemiologic Studies
Obesity
Smoking
Stroke
Myocardial Infarction
Hypertension
Incidence
Therapeutics
Tobacco Products
Insulin

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Emerging therapeutic targets in diabetic vascular disease. / Schmidt, Ann Marie; Stern, David.

In: Expert Opinion on Therapeutic Targets, Vol. 3, No. 3, 01.09.1999, p. 483-493.

Research output: Contribution to journalReview article

@article{402be22674ed44f69fbd0c49046563fd,
title = "Emerging therapeutic targets in diabetic vascular disease",
abstract = "Diabetes affects nearly 14 m persons in the United States alone; worldwide, the incidence of diabetes is on the rise. It is a heterogeneous disorder of impaired insulin production/sensitivity and is associated with enhanced development of accelerated micro- and macrovasculature disease. Multiple epidemiologic studies have demonstrated that even after correction of typical risk factors, such as obesity, hyperlipidaemia, hypertension and cigarette smoking, patients with diabetes continue to experience enhanced risk of cardiovascular complications [1-2]. Thus, delineation of the factors specific and unique to diabetes that impart increased risk for the development of aggressive heart attacks and strokes is critical for the development of targeted therapy to prevent/delay accelerated macrovascular disease in diabetic patients.",
author = "Schmidt, {Ann Marie} and David Stern",
year = "1999",
month = "9",
day = "1",
doi = "10.1517/14728222.3.3.483",
language = "English (US)",
volume = "3",
pages = "483--493",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Emerging therapeutic targets in diabetic vascular disease

AU - Schmidt, Ann Marie

AU - Stern, David

PY - 1999/9/1

Y1 - 1999/9/1

N2 - Diabetes affects nearly 14 m persons in the United States alone; worldwide, the incidence of diabetes is on the rise. It is a heterogeneous disorder of impaired insulin production/sensitivity and is associated with enhanced development of accelerated micro- and macrovasculature disease. Multiple epidemiologic studies have demonstrated that even after correction of typical risk factors, such as obesity, hyperlipidaemia, hypertension and cigarette smoking, patients with diabetes continue to experience enhanced risk of cardiovascular complications [1-2]. Thus, delineation of the factors specific and unique to diabetes that impart increased risk for the development of aggressive heart attacks and strokes is critical for the development of targeted therapy to prevent/delay accelerated macrovascular disease in diabetic patients.

AB - Diabetes affects nearly 14 m persons in the United States alone; worldwide, the incidence of diabetes is on the rise. It is a heterogeneous disorder of impaired insulin production/sensitivity and is associated with enhanced development of accelerated micro- and macrovasculature disease. Multiple epidemiologic studies have demonstrated that even after correction of typical risk factors, such as obesity, hyperlipidaemia, hypertension and cigarette smoking, patients with diabetes continue to experience enhanced risk of cardiovascular complications [1-2]. Thus, delineation of the factors specific and unique to diabetes that impart increased risk for the development of aggressive heart attacks and strokes is critical for the development of targeted therapy to prevent/delay accelerated macrovascular disease in diabetic patients.

UR - http://www.scopus.com/inward/record.url?scp=80052016189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052016189&partnerID=8YFLogxK

U2 - 10.1517/14728222.3.3.483

DO - 10.1517/14728222.3.3.483

M3 - Review article

AN - SCOPUS:80052016189

VL - 3

SP - 483

EP - 493

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 3

ER -